Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Detection of Minimal Residual Disease in B Lymphoblastic Leukemia by High-Throughput Sequencing of <i>IGH</i>

26 Jun 2014

Abstract excerpt

PURPOSE: High-throughput sequencing (HTS) of immunoglobulin heavy-chain genes (IGH) in unselected clinical samples for minimal residual disease (MRD) in B lymphoblastic leukemia (B-ALL) has not been tested. As current MRD-detecting methods such as flow cytometry or patient-specific qPCR are complex or difficult to standardize in the clinical laboratory, sequencing may enhance clinical prognostication....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Lymphoblastic Leukemia research
Share to Acute Myeloid Leukemia Research
Share to Lymphoma Diagnosis and Treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 24970842
DOI: 10.1158/1078-0432.ccr-13-3231

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Detection of Minimal Residual Disease in B Lymphoblastic Leukemia by High-Throughput Sequencing of <i>IGH</i>PMID 24970842Read ↗

Minimal residual disease detection by next-generation sequencing of different immunoglobulin gene rearrangements in pediatric B-ALLSemantic proximity Read ↗

Minimal Residual Disease Detection and Evolved IGH Clones Analysis in Acute B Lymphoblastic Leukemia Using IGH Deep SequencingSemantic proximity Read ↗

High-Throughput Sequencing Detects Minimal Residual Disease in Acute T Lymphoblastic LeukemiaSemantic proximity Read ↗

High-throughput VDJ sequencing for quantification of minimal residual disease in chronic lymphocytic leukemia and immune reconstitution assessmentSemantic proximity Read ↗

Clinical implication of minimal residual disease assessment by next-generation sequencing-based immunoglobulin clonality assay in pediatric B-acute lymphoblastic leukemiaSemantic proximity Read ↗

Reading the B-cell receptor immunome in chronic lymphocytic leukemia: revelations and applications.Semantic proximity Read ↗

Sequence analysis of clonal immunoglobulin and T-cell receptor gene rearrangements in children with acute lymphoblastic leukemia at diagnosis and at relapse: implications for pathogenesis and for the clinical utility of PCR-based methods of minimal residual disease detectionSemantic proximity Read ↗

Massive evolution of the immunoglobulin heavy chain locus in children with B precursor acute lymphoblastic leukemiaSemantic proximity Read ↗

Next-generation sequencing for minimal residual disease monitoring in acute myeloid leukemia patients with FLT3-ITD or NPM1 mutations.Semantic proximity Read ↗

Presence of minimal residual disease determined by next-generation sequencing is not a reliable prognostic biomarker in children with acute lymphoblastic leukemiaSemantic proximity Read ↗

Clinical utility of next‐generation sequencing‐based minimal residual disease in paediatric B‐cell acute lymphoblastic leukaemiaSemantic proximity Read ↗

Next-generation antigen receptor sequencing of paired diagnosis and relapse samples of B-cell acute lymphoblastic leukemia: Clonal evolution and implications for minimal residual disease target selectionSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.